حافظ با حفظ رحمت‌الله مبارک
Iran experiences in providing access and management of medicine at the time of war and sanctions

Prof. Mostafa Ghanei, Director General of Biotechnology Development Council (BDC)
7th World Health Summit Meeting 2019
Sales Trend of the Top Five Therapeutic Chemical Groups
Availability Trends of Cancer Drugs: Sanctions
Policies and Strategies

- Co-operation with the Food and Drug Administration in facilitating joint venture between producing companies
- Policy making to reduce the cost of production in the country
- Encouraging export-centered companies
- Guiding tax exemptions of knowledge-based companies to the research, innovation, and exporting sectors of companies
Iran’s Pharmaceutical Industry at a Glance

- Generic and Brand-Generic Systems
- More than 15,000 Pharmacists
- More than 186 Trading Companies
- About 36 Distributing Companies
- More than 107 Manufacturing Companies
- National self-sufficiency at 96% FP and 50% API
- Possessing Higher than 9 billion USD Drug Economy
- Strict Qualitative and Quantitative Controls on the Pharmaceutical Industry
- Possessing "National Drug Policy" more than Two Decades
Iran Position in Biotechnology Drugs

- Total No. of biotechnology Drugs developed in world : 160
- Total No. of biotechnology Drugs produced in Iran : 22
- Iran’s position in Asia: 2nd

<table>
<thead>
<tr>
<th>Biotechnology Drugs Producing Countries in Asia</th>
<th>No. of Produced Drugs in Asia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Japan</td>
<td>31</td>
</tr>
<tr>
<td>Iran</td>
<td>22</td>
</tr>
<tr>
<td>India</td>
<td>12</td>
</tr>
<tr>
<td>South Korea</td>
<td>10</td>
</tr>
<tr>
<td>China</td>
<td>10</td>
</tr>
</tbody>
</table>
Thanks for Your Attention